PF-Atlas › Clinical Trials › NCT01627002
A Phase 1, First in Human Study to Investigate the Safety and Tolerability of PA401
PA401 · Phase 1
Registry ID
NCT01627002
Phase
Phase 1
Status
Terminated
Drug / intervention
PA401
Sponsor
ProtAffin Biotechnologie AG
Start
2012-05
Enrollment
49
Locations
1
About this trial
The purpose of this study is to examine the safety, tolerability, immunogenicity and the way the body absorbs, distributes, breaks down and excretes various increasing single and multiple subcutaneous doses of PA401 in healthy subjects. This study will also look at the effect of PA401 on inflammation in the lungs following an inhaled lipopolysaccharide (LPS) challenge (LPS is a bacterial cell wall fragment) and sputum induction (a procedure performed to help to cough up sputum (phlegm)) after a single subcutaneous dose of two dose levels.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT01627002 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.